ArticleSmall (Weinheim an der Bergstrasse, Germany)2025
Tribenzoylarsine - A Benign Arsenic Precursor for InAs Nanocrystals.
Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Large Colloidal InAs Nanocrystals Synthesized with a Grignard Reagent.Chemistry of materials : a publication of the American Chemical Society · 2026Article
- Tribenzoylarsine - A Benign Arsenic Precursor for InAs Nanocrystals.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
III-V semiconductor nanocrystals (NCs) have emerged as a benign alternative to II-VI and IV-VI NCs, which are restricted due to the toxicity of the comprising elements. While InP NCs advanced significantly, the development of infrared-emitting InAs NCs has been relatively slow-paced. This is due to the synthetic challenges arising from the highly covalent bonding in InAs and the limited range of available arsenic sources. Most importantly, current syntheses rely on hazardous pyrophoric and costly reagents, which hampers their wider adoption. In this work, the synthesis of tribenzoylarsine is reported, which can be used as a novel nonvolatile, nonpyrophoric, and hence safer precursor for metal arsenide nanoparticles. Tribenzoylarsine reacts with indium oleate without additional reducing agents yielding small (≈2 nm) InAs NCs. By tuning synthesis parameters (e.g., the addition of zinc oleate or using continuous injection) it is possible to cover the photoluminescence range of 630-780 nm with full width at half maximum as low as 170-210 meV, which is a very competitive value to the existing synthetic approaches. Along with the significantly safer nature of tribenzoylarsine and the great potential for synthesis optimization, this makes it a very promising alternative to the currently used arsenic precursors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.